Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Collaborator: Mitsubishi Tanabe Pharma Corporation
• Treatments: Fingolimod Hydrochloride

Criteria

Inclusion Criteria:

• Male and female patients aged 18-60

• Patients with a diagnosis of multiple sclerosis

Exclusion Criteria:

• Patients with a history or presence of chronic disease of the immune system other than MS

• Patients with a history or presence of malignancy, pulmonary or heart disease, etc.

• Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply